

Sumatriptan

for the treatment of acute migraine attacks

Technology Guidance from the MOH Drug Advisory Committee

Guidance Recommendations

Following an evaluation of sumatriptan for the treatment of acute migraine attacks, sumatriptan 50mg tablet is recommended for listing on the MOH Standard Drug List 2 (SDL2) by the MOH Drug Advisory Committee in view of its clinically superior outcomes when used in combination with naproxen compared with either sumatriptan or naproxen monotherapy, and the low cost of subsidy.

This recommendation means that subsidies will apply to sumatriptan for the indications registered in Singapore:

- Acute relief of migraine attacks with or without aura, including the acute treatment of migraine attacks associated with the menstrual period in women.

Published on 3 May 2017

About the Agency

The Agency for care effectiveness (ACE) is the national health technology assessment agency in Singapore residing within the Ministry of Health. It conducts evaluations to inform the subsidy of treatments, and produces guidance on the appropriate use of treatments for public hospitals and institutions in Singapore. When using the guidance, the responsibility for making decisions appropriate to the circumstances of the individual patient remains with the healthcare professional.

Find out more about ACE at www.ace-hta.gov.sg/about

© Agency for Care Effectiveness, Ministry of Health, Republic of Singapore

All rights reserved. Reproduction of this publication in whole or in part in any material form is prohibited without the prior written permission of the copyright holder. Application to reproduce any part of this publication should be addressed to:

Head (Evaluation)
Agency for Care Effectiveness
Email: ACE_HTA@moh.gov.sg

In citation, please credit the Ministry of Health when you extract and use the information or data from the publication.